⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
SBILIFE - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.9
| Stock Code | SBILIFE | Market Cap | 1,95,704 Cr. | Current Price | 1,951 ₹ | High / Low | 2,133 ₹ |
| Stock P/E | 78.9 | Book Value | 190 ₹ | Dividend Yield | 0.14 % | ROCE | 16.9 % |
| ROE | 15.1 % | Face Value | 10.0 ₹ | DMA 50 | 1,998 ₹ | DMA 200 | 1,908 ₹ |
| Chg in FII Hold | 0.03 % | Chg in DII Hold | 0.02 % | PAT Qtr | 577 Cr. | PAT Prev Qtr | 495 Cr. |
| RSI | 46.5 | MACD | -28.7 | Volume | 7,10,653 | Avg Vol 1Wk | 9,89,573 |
| Low price | 1,431 ₹ | High price | 2,133 ₹ | PEG Ratio | 4.64 | Debt to equity | 0.00 |
| 52w Index | 74.1 % | Qtr Profit Var | 4.71 % | EPS | 24.7 ₹ | Industry PE | 76.2 |
📊 Financial Overview
- Revenue & Profit Growth: Quarterly PAT rose from ₹495 Cr. to ₹577 Cr. (4.71% growth).
- Margins: ROE at 15.1% and ROCE at 16.9% show healthy efficiency.
- Debt: Debt-to-equity ratio of 0.00 → debt-free balance sheet.
- Cash Flow: Strong due to insurance premium inflows and low leverage.
- Return Metrics: EPS at ₹24.7, consistent profitability.
💹 Valuation Indicators
- P/E Ratio: 78.9 vs Industry PE of 76.2 → slightly overvalued.
- P/B Ratio: Price ₹1,951 / Book Value ₹190 ≈ 10.27.
- PEG Ratio: 4.64 → expensive relative to growth.
- Intrinsic Value: Current valuation stretched, limited margin of safety.
🏢 Business Model & Competitive Advantage
- Operates as a leading life insurance provider under SBI brand.
- Strong distribution network via SBI branches and bancassurance partnerships.
- Competitive advantage lies in brand trust, scale, and diversified product portfolio.
- Low debt enhances financial stability, but high valuation is a concern.
📈 Entry Zone Recommendation
- Technicals: RSI at 46.5 (neutral), MACD negative, price below 50DMA (1,998) but above 200DMA (1,908).
- Entry Zone: Attractive accumulation near ₹1,850–1,900 for long-term investors.
- Holding Guidance: Suitable for long-term holding given India’s rising insurance penetration, but valuation risk persists.
✅ Positive
- Debt-free balance sheet.
- Strong brand recall and distribution through SBI.
- Quarterly PAT growth and consistent profitability.
- Institutional investors increasing stake (FII +0.03%, DII +0.02%).
⚠️ Limitation
- High P/E (78.9) and P/B (10.27) multiples.
- Low dividend yield (0.14%).
- Quarterly profit growth modest at 4.71%.
📉 Company Negative News
- Stock corrected from ₹2,133 to ₹1,951, showing weakness.
- MACD negative, indicating bearish momentum.
📈 Company Positive News
- Quarterly PAT improved to ₹577 Cr.
- Strong institutional investor confidence.
- Expanding insurance penetration in India supports growth.
🌐 Industry
- Life insurance industry in India is underpenetrated, offering long-term growth potential.
- Industry PE at 76.2 indicates sector trades at high valuations.
- Government focus on financial inclusion supports expansion.
🔎 Conclusion
- SBILIFE is financially strong, debt-free, and well-positioned in India’s growing insurance market.
- Valuations remain stretched, limiting near-term upside.
- Best considered as a long-term hold with entry near ₹1,850–1,900 for margin of safety.